[5]Patel JD, Meng J, Phani S, et al: Clinical characteristics, real-world treatment patterns, and clinical outcomes among patients with previously treated metastatic or unresectable EGFR-mutated non-small cell lung cancer in the United States. 2023 AACR abstract 6754. [6]Scharpenseel H, Hanss...
In the treatment of early breast cancer adjuvant trastuzumab reduces the risk of recurrence and death if added to chemotherapy. Trastuzumab can be administered in different ways but the concomitant administration with chemotherapy (taxanes), compared to sequential administration, reduces the risk of ...
[9] Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2‑positive metastatic breast cancer administered a...
肿瘤细胞的HER3表达具有时空异质性,在存档标本(Archival)和治疗前(Pre-treatment)标本中,肿瘤的HER3阳性率既有升高也有降低。尽管如此,HER3表达的动态变化并不影响HER3-DXd治疗的疗效,在PR患者中,既有HER3表达增加的,也有HER3表达降低的。 △患者HER3表达阳性率的动态变化和BOR 安全性 HER3-DXd治疗的安全性可控。
肿瘤细胞的HER3表达具有时空异质性,在存档标本(Archival)和治疗前(Pre-treatment)标本中,肿瘤的HER3阳性率既有升高也有降低。尽管如此,HER3表达的动态变化并不影响HER3-DXd治疗的疗效,在PR患者中,既有HER3表达增加的,也有HER3表达降低的。 △患者HER3表达阳性率的动态变化和BOR ...
肿瘤细胞的HER3表达具有时空异质性,在存档标本(Archival)和治疗前(Pre-treatment)标本中,肿瘤的HER3阳性率既有升高也有降低。尽管如此,HER3表达的动态变化并不影响HER3-DXd治疗的疗效,在PR患者中,既有HER3表达增加的,也有HER3表达降低的。 △患者HER3表达阳性率的动态变化和BOR ...
Toddlers are known for being a little wild, a little cranky, and a lot unpredictable, but they are also tiny beings of pure love and cuteness that can make even the hardest day disappear. And whenOlivia Munnwas diagnosed withbreast cancerand went through grueling treatment, it was her toddle...
Throughout her treatment, Heather felt the embrace of care, support and hope from everyone she encountered atNorton Cancer Institute. “I felt it for myself; I witnessed it in the interactions with others around me,” Heather said. “It was a part of who they (the care ...
8. Saura Manich C, O’Shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre...
2. XuB, YanM, MaF, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3):351-360. ...